Rationale: There are no direct comparisons of sotatercept to add-on therapies approved for
PAH. Objective: This study aimed to compare the efficacy and safety of add-on sotatercept …

Pulmonary arterial hypertension (PAH) is characterized by increased pulmonary vascular
resistance (PVR), right ventricular (RV) failure and premature death. Compounds with …

The treatment landscape for PAH has evolved dramatically over the past 30 years. 3
Medications targeting the endothelin, nitric oxide, and prostacyclin pathways have been …

Extract Pulmonary vascular remodelling and dysfunction are hallmarks of pulmonary arterial
hypertension (PAH), a rare and severe form of pre-capillary pulmonary hypertension …

The field of pulmonary hypertension has been transformed beyond recognition over the past
30 years. Advances in the understanding of pathophysiology has led to the testing of …

Purpose The underlying causes of pulmonary arterial hypertension (PAH) often remain
obscure. Addressing PAH with effective treatments presents a formidable challenge. Studies …

Aims Pulmonary hypertension (PH) is characterised by an increase in pulmonary arterial
pressure, ultimately leading to right ventricular failure and death. We have previously shown …

Background Pulmonary arterial hypertension (PAH)-targeted therapies exert significant
haemodynamic changes; however, systematic synthesis is currently lacking. Methods We …

Background Pulmonary arterial hypertension (PAH) is a complex and progressive illness
that has a multifaceted origin, significant fatality rates, and profound effects on health. The …

Sarcoidosis-associated pulmonary hypertension (SAPH) is a very severe complication of the
disease, largely impacting its morbidity and being one of its strongest predictors of mortality …